Seeking novel treatments for Complement-related diseases including age-related macular degeneration (AMD) and creation of spin out company Complement Therapeutics

Impact: Health and wellbeing, Economic


In March 2020, the spin out company Complement Therapeutics was formed based on our research into the ways the Complement System (also known as the complement cascade) which is part of the immune system) works, and how it is dysregulated in age-related macular degeneration. Complement Therapeutics aims to develop innovative and effective therapies to address unmet needs in complement mediated diseases such as dry age-related macular degeneration AMD which affects millions and for which there is currently no effective treatment.

Its lead product is CTx001, an innovative gene therapy for the treatment of Geographic Atrophy (GA) secondary to dry AMD.

In February 2022, the company secured EUR 5 million in seed financing.

In November 2022 MHRA MHRA granted Complement Therapeutics an Innovation Passport under the new accelerated Innovative Licensing and Access Pathway (ILAP) for CTx001 to accelerate Gene Therapy for GA (ILAP is designed to optimise the development and expedite the evaluation of innovative medicines for patients with high unmet need).

In April 2023 the company secured a further EUR 72 million financing to continue the development of CTx001 and grow it's lab space in Stevenage.
Impact date2019
Category of impactHealth and wellbeing, Economic
Impact levelEngagement

Research Beacons, Institutes and Platforms

  • Manchester Institute for Collaborative Research on Ageing